Disease & disorder

herpes zoster

MONDO:0005609

A common dermal and neurologic disorder caused by reactivation of the varicella-zoster virus that has remained dormant within dorsal root ganglia, often for decades, after the patient's initial exposure to the virus in the form of varicella (chickenpox). It is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area.

Clinical trials17
Recruiting2
Drug concepts studied1
Synonyms3

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Shingles

Shingles, also known as herpes zoster or zona, is a viral disease characterized by a painful skin rash with blisters in a localized area. Typically the rash occurs in a single, wide mark either on the left or right side of the body or face. Two to four days before the rash occurs, there may be tingling or local pain in the area. Other common symptoms are fever, headache, and tiredness. The rash usually heals within four weeks, but some people develop ongoing nerve pain which can last for months or years, a condition called postherpetic neuralgia (PHN). In those with poor immune function the rash may occur widely. If the rash involves the eye, vision loss may occur. Shingles is caused by the varicella zoster virus (VZV) that also causes chickenpox. In the case of chickenpox, also called varicella, the initial infection with the virus typically occurs during childhood or adolescence. Once the chickenpox has resolved, the virus can remain dormant (inactive) in human nerve cells (dorsal root ganglia or cranial nerves) for years or decades, after which it may reactivate and travel along nerve bodies to nerve endings in the skin, producing blisters. During an outbreak of shingles, exposure to the varicella virus found in shingles blisters can cause chickenpox in someone who has not yet had chickenpox, although that person will not develop shingles, at least on the first infection. How the virus subsequently re-activates is not well understood. The disease has been recognized since ancient times. Risk factors for reactivation of the dormant virus include old age, poor immune fu...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

17 shown
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandNCT07502560 · 2026-03-31
RECRUITING
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control PopulationNCT05580458 · 2023-03-13
RECRUITING
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis PatientsNCT05596526 · 2022-12-01
UNKNOWN
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER CancerNCT04540081 · 2020-10-05
COMPLETED
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia AreataNCT04239521 · 2020-10-01
COMPLETED
HIV Indicator Diseases in Hospital and Primary CareNCT05225493 · 2020-01-01
UNKNOWN
Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic PatientsNCT03016884 · 2017-01-01
UNKNOWN
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of BergamoNCT02902822 · 2016-10-01
COMPLETED
Postherpetic Neuralgia After Herpes Zoster and Incident Dementia RiskNCT07399288 · 2015-10-01
COMPLETED
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using AbataceptNCT03604406 · 2014-05-08
COMPLETED
Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-StudyNCT01213810 · 2010-12-01
WITHDRAWN
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected SubjectsNCT01165203 · 2010-09-30
COMPLETED
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral TherapyNCT00851786 · 2009-04-29
COMPLETED
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)NCT00233155 · 2005-08-01
COMPLETED
Dextromethorphan Versus Placebo for Neuropathic PainNCT00001344 · 1993-03-01
COMPLETED
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic PainNCT00089557
TERMINATED
Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic PainNCT00082316
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.